Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in…

Posted: October 7, 2024 at 2:37 am

London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca’s Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has delivered positive results. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction1 in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.

Go here to see the original:
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in...

Related Posts